Table 4.
Adjusted regression model for predictors for 30‐day mortality. Values are fraction (proportion) or OR (95%CI)
| Mortality | OR (95%CI) | p value | |
|---|---|---|---|
| VTE status | |||
| No VTE | 2047/127,267 (1.6%) | ||
| VTE | 594/742 (20.0%) | 5.42 (4.36–6.75) | <0.001 |
| SARS‐CoV‐2 status | |||
| No SARS‐CoV‐2 | 1845/123,591 (1.5%) | ||
| Peri‐operative SARS‐CoV‐2 | 256/2317 (11.1%) | 2.38 (2.00–2.82) | <0.001 |
| Recent SARS‐CoV‐2 | 70/953 (7.4%) | 2.78 (2.09–3.71) | <0.001 |
| Previous SARS‐CoV‐2 | 24/1148 (2.1%) | 1.13 (0.72–1.76) | 0.597 |
| Pneumonia | |||
| No | 1666/125,337 (1.3%) | ||
| Yes | 529/2672 (19.8%) | 5.28 (4.65–6.00) | <0.001 |
| Age; y | |||
| 18–49 | 429/57,557 (0.8%) | ||
| 50–69 | 757/43,130 (1.8%) | 1.62 (1.41–1.86) | <0.001 |
| ≥70 | 1009/27,320 (3.7%) | 2.67 (2.31–3.10) | <0.001 |
| Sex | |||
| Female | 956/68,825 (1.4%) | ||
| Male | 1239/59,180 (2.1%) | 1.06 (0.96–1.16) | 0.269 |
| ASA physical status | |||
| 1–2 | 543/94,020 (0.6%) | ||
| 3–5 | 1651/33,946 (4.9%) | 4.32 (3.84–4.86) | <0.001 |
| Smoking | |||
| No | 1796/105,399 (1.7%) | ||
| Yes | 387/20,045 (1.9%) | 1.16 (1.02–1.32) | 0.021 |
| Respiratory comorbidities | |||
| No | 1843/115,688 (1.6%) | ||
| Yes | 349/12,223 (2.9%) | 0.95 (0.83–1.08) | 0.410 |
| Congestive heart failure | |||
| No | 1859/122,962 (1.5%) | ||
| Yes | 336/5019 (6.7%) | 1.54 (1.34–1.78) | < 0.001 |
| Cerebral vascular disease | |||
| No | 1940/123,465 (1.6%) | ||
| Yes | 255/4516 (5.7%) | 1.37 (1.18–1.60) | < 0.001 |
| Chronic kidney disease | |||
| No | 1884/124,644 (1.5%) | ||
| Yes | 311/3337 (9.3%) | 2.32 (2.00–2.69) | <0.001 |
| Ischaemic heart disease | |||
| No | 1677/116,778 (1.4%) | ||
| Yes | 518/11,203 (4.6%) | 1.01 (0.90–1.14) | 0.842 |
| Indication | |||
| Benign | 1174/78,720 (1.5%) | ||
| Malignancy | 569/24,112 (2.4%) | 1.90 (1.68–2.14) | <0.001 |
| Trauma | 413/15,236 (2.7%) | 0.91 (0.80–1.04) | 0.160 |
| Obstetric | 39/9938 (0.4%) | 0.39 (0.27–0.55) | <0.001 |
| Grade of surgery | |||
| Minor | 388/48,596 (0.8%) | ||
| Major | 1807/79,388 (2.3%) | 1.80 (1.59–2.03) | <0.001 |
| Urgency of surgery | |||
| Elective | 666/89,540 (0.7%) | ||
| Emergency | 1535/38,462 (4.0%) | 5.62 (5.03–6.27) | <0.001 |
| Anaesthetic | |||
| Local/regional | 306/35,721 (0.9%) | ||
| General | 1888/92,235 (2.1%) | 1.90 (1.65–2.18) | <0.001 |
| Country income | |||
| High | 1196/85,055 (1.4%) | ||
| Upper middle | 463/21,569 (2.2%) | 2.43 (2.15–2.75) | <0.001 |
| Lower middle/low | 536/21,385 (2.5%) | 4.73 (4.17–5.37) | <0.001 |
VTE, venous thromboembolism.
Peri‐operative SARS‐CoV‐2, 7 days before to 30 days after surgery; recent SARS‐CoV‐2, 1–6 weeks before surgery; previous SARS‐CoV‐2, ≥ 7 weeks before surgery.